LymphedemaV1, PascalFrancis, Corpus, bibRecord, 000960

Edema volume, not timing, is the key to success in lymphedema treatment

Identifieur interne : 000960 ( PascalFrancis/Corpus ); précédent : 000959; suivant : 000961

Edema volume, not timing, is the key to success in lymphedema treatment

Auteurs : S. M. Ramos ; L. S. O'Donnell ; G. Knight

Source :

The American journal of surgery [ 0002-9610 ] ; 1999.

RBID : Pascal:00-0008016

Descripteurs français

Pascal (Inist)
- Lymphoedème, Carcinome, Glande mammaire, Mastectomie, Radiothérapie, Survie, Pronostic, Homme.

English descriptors

KwdEn :
- Carcinoma, Human, Lymphedema, Mammary gland, Mastectomy, Prognosis, Radiotherapy, Survival.

Abstract

BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0002-9610`
A02	`01`			`@0 AJSUAB`
A03		`1`		`@0 Am. j. surg.`
A05				`@2 178`
A06				`@2 4`
A08	`01`	`1`	`ENG`	`@1 Edema volume, not timing, is the key to success in lymphedema treatment`
A11	`01`	`1`		`@1 RAMOS (S. M.)`
A11	`02`	`1`		`@1 O'DONNELL (L. S.)`
A11	`03`	`1`		`@1 KNIGHT (G.)`
A14	`01`			`@1 Department of Surgery, University of New Mexico School of Medicine @2 Albuquerque, New Mexico @3 USA @Z 1 aut.`
A14	`02`			`@1 HealthSouth-Albuquerque Lymphedema Treatment Program @2 Albuquerque, New Mexico @3 USA @Z 1 aut. @Z 2 aut.`
A14	`03`			`@1 Vitale Therapeutics, Inc. @2 Albuquerque, New Mexico @3 USA @Z 3 aut.`
A20				`@1 311-315`
A21				`@1 1999`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5070 @5 354000080772660100`
A44				`@0 0000 @1 © 2000 INIST-CNRS. All rights reserved.`
A45				`@0 22 ref.`
A47	`01`	`1`		`@0 00-0008016`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 The American journal of surgery`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.
C02	`01`	`X`		`@0 002B25K`
C02	`02`	`X`		`@0 002B20E02`
C03	`01`	`X`	`FRE`	`@0 Lymphoedème @5 01`
C03	`01`	`X`	`ENG`	`@0 Lymphedema @5 01`
C03	`01`	`X`	`SPA`	`@0 Linfedema @5 01`
C03	`02`	`X`	`FRE`	`@0 Carcinome @5 04`
C03	`02`	`X`	`ENG`	`@0 Carcinoma @5 04`
C03	`02`	`X`	`SPA`	`@0 Carcinoma @5 04`
C03	`03`	`X`	`FRE`	`@0 Glande mammaire @5 05`
C03	`03`	`X`	`ENG`	`@0 Mammary gland @5 05`
C03	`03`	`X`	`SPA`	`@0 Glándula mamaria @5 05`
C03	`04`	`X`	`FRE`	`@0 Mastectomie @5 07`
C03	`04`	`X`	`ENG`	`@0 Mastectomy @5 07`
C03	`04`	`X`	`SPA`	`@0 Mastectomía @5 07`
C03	`05`	`X`	`FRE`	`@0 Radiothérapie @5 08`
C03	`05`	`X`	`ENG`	`@0 Radiotherapy @5 08`
C03	`05`	`X`	`SPA`	`@0 Radioterapia @5 08`
C03	`06`	`X`	`FRE`	`@0 Survie @5 09`
C03	`06`	`X`	`ENG`	`@0 Survival @5 09`
C03	`06`	`X`	`SPA`	`@0 Sobrevivencia @5 09`
C03	`07`	`X`	`FRE`	`@0 Pronostic @5 17`
C03	`07`	`X`	`ENG`	`@0 Prognosis @5 17`
C03	`07`	`X`	`SPA`	`@0 Pronóstico @5 17`
C03	`08`	`X`	`FRE`	`@0 Homme @5 20`
C03	`08`	`X`	`ENG`	`@0 Human @5 20`
C03	`08`	`X`	`SPA`	`@0 Hombre @5 20`
C07	`01`	`X`	`FRE`	`@0 Appareil circulatoire pathologie @5 37`
C07	`01`	`X`	`ENG`	`@0 Cardiovascular disease @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Lymphatique pathologie @5 38`
C07	`02`	`X`	`ENG`	`@0 Lymphatic vessel disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Linfático patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @5 45`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @5 45`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @5 45`
C07	`04`	`X`	`FRE`	`@0 Glande mammaire pathologie @2 NM @5 46`
C07	`04`	`X`	`ENG`	`@0 Mammary gland diseases @2 NM @5 46`
C07	`04`	`X`	`SPA`	`@0 Glándula mamaria patología @2 NM @5 46`
C07	`05`	`X`	`FRE`	`@0 Chirurgie @5 53`
C07	`05`	`X`	`ENG`	`@0 Surgery @5 53`
C07	`05`	`X`	`SPA`	`@0 Cirugía @5 53`
N21				`@1 003`

Format Inist (serveur)

NO :	PASCAL 00-0008016 INIST
ET :	Edema volume, not timing, is the key to success in lymphedema treatment
AU :	RAMOS (S. M.); O'DONNELL (L. S.); KNIGHT (G.)
AF :	Department of Surgery, University of New Mexico School of Medicine/Albuquerque, New Mexico/Etats-Unis (1 aut.); HealthSouth-Albuquerque Lymphedema Treatment Program/Albuquerque, New Mexico/Etats-Unis (1 aut., 2 aut.); Vitale Therapeutics, Inc./Albuquerque, New Mexico/Etats-Unis (3 aut.)
DT :	Publication en série; Niveau analytique
SO :	The American journal of surgery; ISSN 0002-9610; Coden AJSUAB; Etats-Unis; Da. 1999; Vol. 178; No. 4; Pp. 311-315; Bibl. 22 ref.
LA :	Anglais
EA :	BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.
CC :	002B25K; 002B20E02
FD :	Lymphoedème; Carcinome; Glande mammaire; Mastectomie; Radiothérapie; Survie; Pronostic; Homme
FG :	Appareil circulatoire pathologie; Lymphatique pathologie; Tumeur maligne; Glande mammaire pathologie; Chirurgie
ED :	Lymphedema; Carcinoma; Mammary gland; Mastectomy; Radiotherapy; Survival; Prognosis; Human
EG :	Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Mammary gland diseases; Surgery
SD :	Linfedema; Carcinoma; Glándula mamaria; Mastectomía; Radioterapia; Sobrevivencia; Pronóstico; Hombre
LO :	INIST-5070.354000080772660100
ID :	00-0008016

Links to Exploration step

Pascal:00-0008016

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Edema volume, not timing, is the key to success in lymphedema treatment</title>
<author><name sortKey="Ramos, S M" sort="Ramos, S M" uniqKey="Ramos S" first="S. M." last="Ramos">S. M. Ramos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of New Mexico School of Medicine</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>HealthSouth-Albuquerque Lymphedema Treatment Program</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Donnell, L S" sort="O Donnell, L S" uniqKey="O Donnell L" first="L. S." last="O'Donnell">L. S. O'Donnell</name>
<affiliation><inist:fA14 i1="02"><s1>HealthSouth-Albuquerque Lymphedema Treatment Program</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knight, G" sort="Knight, G" uniqKey="Knight G" first="G." last="Knight">G. Knight</name>
<affiliation><inist:fA14 i1="03"><s1>Vitale Therapeutics, Inc.</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">00-0008016</idno>
<date when="1999">1999</date>
<idno type="stanalyst">PASCAL 00-0008016 INIST</idno>
<idno type="RBID">Pascal:00-0008016</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000960</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Edema volume, not timing, is the key to success in lymphedema treatment</title>
<author><name sortKey="Ramos, S M" sort="Ramos, S M" uniqKey="Ramos S" first="S. M." last="Ramos">S. M. Ramos</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of New Mexico School of Medicine</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="02"><s1>HealthSouth-Albuquerque Lymphedema Treatment Program</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="O Donnell, L S" sort="O Donnell, L S" uniqKey="O Donnell L" first="L. S." last="O'Donnell">L. S. O'Donnell</name>
<affiliation><inist:fA14 i1="02"><s1>HealthSouth-Albuquerque Lymphedema Treatment Program</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Knight, G" sort="Knight, G" uniqKey="Knight G" first="G." last="Knight">G. Knight</name>
<affiliation><inist:fA14 i1="03"><s1>Vitale Therapeutics, Inc.</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">The American journal of surgery</title>
<title level="j" type="abbreviated">Am. j. surg.</title>
<idno type="ISSN">0002-9610</idno>
<imprint><date when="1999">1999</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">The American journal of surgery</title>
<title level="j" type="abbreviated">Am. j. surg.</title>
<idno type="ISSN">0002-9610</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Carcinoma</term>
<term>Human</term>
<term>Lymphedema</term>
<term>Mammary gland</term>
<term>Mastectomy</term>
<term>Prognosis</term>
<term>Radiotherapy</term>
<term>Survival</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lymphoedème</term>
<term>Carcinome</term>
<term>Glande mammaire</term>
<term>Mastectomie</term>
<term>Radiothérapie</term>
<term>Survie</term>
<term>Pronostic</term>
<term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0002-9610</s0>
</fA01>
<fA02 i1="01"><s0>AJSUAB</s0>
</fA02>
<fA03 i2="1"><s0>Am. j. surg.</s0>
</fA03>
<fA05><s2>178</s2>
</fA05>
<fA06><s2>4</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Edema volume, not timing, is the key to success in lymphedema treatment</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>RAMOS (S. M.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>O'DONNELL (L. S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KNIGHT (G.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Surgery, University of New Mexico School of Medicine</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>HealthSouth-Albuquerque Lymphedema Treatment Program</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Vitale Therapeutics, Inc.</s1>
<s2>Albuquerque, New Mexico</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>311-315</s1>
</fA20>
<fA21><s1>1999</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5070</s2>
<s5>354000080772660100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2000 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>22 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>00-0008016</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>The American journal of surgery</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B25K</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20E02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lymphoedème</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lymphedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Linfedema</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Carcinome</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Carcinoma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Carcinoma</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Glande mammaire</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Mammary gland</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Glándula mamaria</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Mastectomie</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Mastectomy</s0>
<s5>07</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Mastectomía</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Radiothérapie</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Radiotherapy</s0>
<s5>08</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Radioterapia</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Survie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Survival</s0>
<s5>09</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Sobrevivencia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Pronostic</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Prognosis</s0>
<s5>17</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Pronóstico</s0>
<s5>17</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Homme</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Human</s0>
<s5>20</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Hombre</s0>
<s5>20</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Appareil circulatoire pathologie</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Lymphatique pathologie</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Lymphatic vessel disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Linfático patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s5>45</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s5>45</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s5>45</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Glande mammaire pathologie</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Mammary gland diseases</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Glándula mamaria patología</s0>
<s2>NM</s2>
<s5>46</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Chirurgie</s0>
<s5>53</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Surgery</s0>
<s5>53</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Cirugía</s0>
<s5>53</s5>
</fC07>
<fN21><s1>003</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 00-0008016 INIST</NO>
<ET>Edema volume, not timing, is the key to success in lymphedema treatment</ET>
<AU>RAMOS (S. M.); O'DONNELL (L. S.); KNIGHT (G.)</AU>
<AF>Department of Surgery, University of New Mexico School of Medicine/Albuquerque, New Mexico/Etats-Unis (1 aut.); HealthSouth-Albuquerque Lymphedema Treatment Program/Albuquerque, New Mexico/Etats-Unis (1 aut., 2 aut.); Vitale Therapeutics, Inc./Albuquerque, New Mexico/Etats-Unis (3 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>The American journal of surgery; ISSN 0002-9610; Coden AJSUAB; Etats-Unis; Da. 1999; Vol. 178; No. 4; Pp. 311-315; Bibl. 22 ref.</SO>
<LA>Anglais</LA>
<EA>BACKGROUND: There are currently between 1 and 2 million breast cancer survivors in the United States. Is the advocated, early intervention the key to successful treatment, or are there other, more important factors? METHODS: Responses to combined decongestive therapy (CDT) for 69 women were analyzed with regard to duration of lymphedema, differences in arm circumference, percent differences in arm volumes, volume of edema, reduction of edema volumes, and duration of treatment. RESULTS: Two- and three-dimensional (2D and 3D) analyses showed little correlation between duration and volume of edema or between duration and response and treatment. However, they did show a correlation between initial volumes of fluid in the tissues and responses. Patients with initial volumes of 250 mL or less had a mean reduction of 78% with CDT, whereas those with initial volumes between 250 and 500 mL had a mean reduction of 56%. CONCLUSION: The key to predicting successful lymphedema treatment is the initial volume of edema in the tissues regardless of whether the intervention is early or late.</EA>
<CC>002B25K; 002B20E02</CC>
<FD>Lymphoedème; Carcinome; Glande mammaire; Mastectomie; Radiothérapie; Survie; Pronostic; Homme</FD>
<FG>Appareil circulatoire pathologie; Lymphatique pathologie; Tumeur maligne; Glande mammaire pathologie; Chirurgie</FG>
<ED>Lymphedema; Carcinoma; Mammary gland; Mastectomy; Radiotherapy; Survival; Prognosis; Human</ED>
<EG>Cardiovascular disease; Lymphatic vessel disease; Malignant tumor; Mammary gland diseases; Surgery</EG>
<SD>Linfedema; Carcinoma; Glándula mamaria; Mastectomía; Radioterapia; Sobrevivencia; Pronóstico; Hombre</SD>
<LO>INIST-5070.354000080772660100</LO>
<ID>00-0008016</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000960 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000960 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:00-0008016
   |texte=   Edema volume, not timing, is the key to success in lymphedema treatment
}}

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Edema volume, not timing, is the key to success in lymphedema treatment

Edema volume, not timing, is the key to success in lymphedema treatment

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri